Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Jun 7, 2022

Dr. Hernan Bazan is the CEO and Co-Founder of South Rampart Pharma and focuses on finding a new way to treat acute and chronic pain with a drug that has no expectation for abuse and is not toxic to the liver, kidneys, or cardiovascular system.

Hernan explains, "This is a tremendous unmet need in that there really has been no innovation in the pain space for over 50 years. Tylenol itself, acetaminophen, Tylenol was born in the '40s and the early '50s and worked by actually someone that was at the NIH that came to visit us a few times, a very well renowned neuroscientist. And he really discovered it incidentally, looking for another pathway, but we won't go into that. And that was adopted by McNeil Laboratories, and then eventually Johnson & Johnson."

"And then, in the '60s and '70s, non-steroidals, non NSAIDs, were marketed as Advil and ibuprofen, and a bunch of NSAIDs were derived. And these are very good medicines for preventing inflammation and treating pain in the short term. The challenge with both of these classes of pain meds is that they have risks."

"And then the third class, obviously, everybody knows about opioids and how they were marketed in the '90s."

@SR_Pharma #Pain #AcutePain #Analgesic #Acetaminophen #Opioid #NSAID #Nontoxic #NonOpioid #NewOrleans

southrampartpharma.com

Download the transcript here

south rampart